Richard Steeves and his people have achieved, and look forward to welcoming them to the STERIS team. "We have great respect for the performance that Dr. "Synergy's focus on achievement, accountability, integrity and innovation has enabled it to deliver remarkable growth for its Customers, people and shareholders since its founding," said Walt Rosebrough, President and CEO of STERIS Corporation. For hospitals, the combination of STERIS's Infection Prevention and Services businesses with Synergy's Hospital Sterilization Services will strengthen the breadth and depth of the offering, accelerating the development of hospital sterilization outsourcing worldwide. For medical device manufacturers, STERIS's Isomedix and Synergy's Applied Sterilization Technologies (AST) will create a leading global supplier to best serve medical device Customers with a network of 58 facilities covering 18 countries. Upon closing, the combined business (New STERIS) will have approximately $2.6 billion in annual revenues from over 60 countries, approximately 14,000 employees, and will bring together geographically complementary businesses. law to acquire Synergy in a cash and stock transaction valued at £19.50 ($31.35) per Synergy share, or a total of approximately $1.9 billion, based on STERIS's closing stock price of $56.38 per share on October 10, 2014. OctoSTERIS Corporation (NYSE:STE) and Synergy Health, plc (LSE:SYR) today announced that STERIS is commencing a "recommended offer" under U.K. and Accelerate International GrowthĬonference Call with Senior Management at 8:30 a.m. Combination Creates a Global Leader in Infection Prevention and SterilizationĪllows Company to Further Invest in the U.S.
0 Comments
Leave a Reply. |